Skip to content

New drug used to treat breast cancer heralded as 'quite groundbreaking'

By Catholic Online (NEWS CONSORTIUM)
4/6/2014 (4 years ago)
Catholic Online (https://www.catholic.org)

Drug cut in half the risk that cancer would worsen

An important treatment option in the fight against breast cancer may be waiting in the wings. Researchers say a new type of drug could help prevent advanced breast cancer from worsening. The potential is great for breast cancer patients, and makes for a potential blockbuster product for Pfizer.

While Pfizer remains in the lead to bring this new class of drugs to market, Novartis has begun late-stage testing of its own CDK 4/6 inhibitor.

While Pfizer remains in the lead to bring this new class of drugs to market, Novartis has begun late-stage testing of its own CDK 4/6 inhibitor.

Highlights

By Catholic Online (NEWS CONSORTIUM)
Catholic Online (https://www.catholic.org)
4/6/2014 (4 years ago)

Published in Health

Keywords: Pfizer, breast cancer, palbociclib


LOS ANGELES, CA (Catholic Online) - Said drug cut in half the risk that cancer would worsen, or progress, researchers said. The median time before the disease progressed or the women died was 20.2 months for those who received the drug, compared with 10.2 months for the control group.

"The magnitude of benefit we are seeing is not something commonly seen in cancer medicine studies," Dr. Richard S. Finn, a principal investigator in the study, says. Finn, an oncologist at the University of California, Los Angeles, called the results "quite groundbreaking."

No child need ever go to bed hungry -- Learn how you can help!

Known as palbociclib, the drug also appeared to prolong survival but not by a statistically significant amount. Those who received the drug lived a median of 37.5 months in contrast with 33.3 months for those in the control group.

The results from the Phase 2, or mid-stage, study were presented here at the annual meeting of the American Association for Cancer Research. Palbociclib is considered a jewel in Pfizer's product pipeline, with analysts predicting annual sales of billions of dollars. Amgen is entitled to an eight percent royalty on sales of the drug.

Some investors may have been letdown due to the drug, partly because they were not quite as good as interim results presented about halfway through the trial. At that point, the difference in median progression-free survival was 26.1 months for palbociclib versus 7.5 months for the control group.

Finn stresses that a statistically significant survival benefit should not have been expected at this point because only 61 of the 165 patients in the trial had died. Patients can use other drugs after leaving the trial, which can dilute any effect of palbociclib.

Palbociclib slows the proliferation of cancer cells by inhibiting the activity of two related enzymes involved in cell division; cyclin-dependent kinases 4 and 6.

While Pfizer remains in the lead to bring this new class of drugs to market, Novartis has begun late-stage testing of its own CDK 4/6 inhibitor. While breast cancer is the initial focus, the drugs are being tested for other cancers.

Breast cancer specialists not involved in the study were encouraged -- but expressed caution. "These results are strikingly positive and with a large potential impact to patients," Dr. José Baselga said in a speech at the conference discussing the results.

Baselga, the physician in chief at the Memorial Sloan-Kettering Cancer Center, also said the results might have been biased because the study investigators, who determined whether tumors had progressed, knew which patients were getting palbociclib.

Dr. Eric P. Winer, chief of women's cancers at the Dana-Farber Cancer Institute in Boston, says larger studies were still needed.

"This is a small Phase 2 trial - not tiny, but not the kind of study that would typically lead to a change in practice," he said.

---


'Help Give every Student and Teacher FREE resources for a world-class Moral Catholic Education'


Copyright 2018 - Distributed by THE CALIFORNIA NETWORK

Pope Francis Prayer Intentions for APRIL 2018
For those who have Responsibility in Economic Matters.
That economists may have the courage to reject any economy of exclusion and know how to open new paths.


Comments


More Health

Department of Defense studying 'Disease X' which could wipe out all humanity Watch

Image of A single doctor or a small program could suffice to create a pathogen that could kill billions of people around the world.

The Department of Defense has received a report that scientists are able to create custom diseases from scratch. The report was ... continue reading


BEHOLD A PALE HORSE: Scientists warn of H7N9 flu that kills 4-in-10 Watch

Image of World health authorities are on the lookout for new cases of H7N9, which has pandemic potential.

Scientists have warned they are monitoring a potentially deadly new disease in China. Dubbed H7N9, the disease is a strain of avian flu ... continue reading


Polio? Rickets? Here's why Victorian-era diseases are coming back Watch

Image of Vaccinations are essential to eradicaitng diseases like polio.

Victorian-era diseases are making a comeback. Declining public health standards, poverty, and skipping vaccinations are to blame. Polio, ... continue reading


Here's what the Catholic Church says about suicide Watch

Image of Suicide is a violation of the Fifth Commandment, but it is a complex problem that requires more than spiritual consideration, but also professional help. Love and affection can also go a long way to helping a person.

Suicides are up 30 percent since 1999. This week, fashion designer Kate Spade and chef Anthony Boudain both hanged themselves. Why are so ... continue reading


Why your boss owes you a vacation, according to science and the Catholic Church Watch

Image of

We all know that one guy who is a workaholic. They show up to work every day, whether tired or sick, they're there. They skip family and ... continue reading


Never Miss any Updates!

Stay up to date with the latest news, information, and special offers.

Information
Learn about Catholic world

Catholic Online
Inform - Inspire - Ignite

Catholic Online Saints
Your saints explained

Catholic Online Prayers
Prayers for every need

Catholic Online Bible
Complete bible online

Catholic Online News
Your news Catholic eye

Daily Reading
Today's bible reading

Lent / Easter
Death & resurrection of Jesus

Advent / Christmas
Birth of Jesus

Rest of Catholic Online
All Catholic world we offer

Services
Products and services we offer

Catholic Online Shopping
Catholic medals, gifts & books

The California Network
Inspiring streaming service

Advertise on Catholic Online
Your ads on catholic.org

Catholic Online Email
Email with Catholic feel

Catholic Online Singles
Safe, secure Catholic dating

The California Studios
World-class post production service

Education
Learn the Catholic way

Catholic Online School
Free Catholic education for all

Student Classes
K-12 & Adult Education Classes

School Teachers
Teacher lesson plans & resources

Support Free Education
Tax deductible support Free education

Socials
Connect with us online

Catholic Online on Facebook
Catholic social network

Catholic Online on Twitter
Catholic Tweets

Catholic Online on YouTube
Enjoy our videos

Catholic Online on Instagram
Shared Catholic moments

Catholic Online on Pinterest
Catholic ideas style inspiration

Catholic Online Logo

Copyright 2018 Catholic Online. All materials contained on this site, whether written, audible or visual are the exclusive property of Catholic Online and are protected under U.S. and International copyright laws, © Copyright 2018 Catholic Online. Any unauthorized use, without prior written consent of Catholic Online is strictly forbidden and prohibited.